Hippocratic AI, a company which develops safety-focused large language models (LLMs) for healthcare, has closed a $53m Series A investment round, co-led by Premji Invest and General Catalyst.
This investment, which values the company at $500m, brings its total funding to $120m.
Go deeper with GlobalData
SV Angel and Memorial Hermann Health System, along with current investors Andreessen Horowitz Bio + Health, WellSpan Health, Cincinnati Children’s, and Universal Health Services, also contributed to the oversubscribed round.
In addition, the company has released its first product, a generative AI-powered staffing marketplace, to support phase three clinician-driven safety testing.
This product is designed to address critical healthcare staffing shortages by allowing health systems and other stakeholders to employ AI agents for low-risk, non-diagnostic, patient-facing services.
See Also:
According to Hippocratic AI, the initial roles these AI agents will fill include health risk assessments, social determinants of health surveys, chronic care management and post-discharge follow-up for conditions like congestive heart failure and kidney disease, among other responsibilities.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHowever, these agents will not interact with patients unsupervised until they have completed phase three of the company’s safety testing protocol.
The new capital will be instrumental in funding these extensive safety tests and further refining the product.
The latest decision to advance to phase three testing was based on the encouraging outcomes of the initial two phases.
Phase one involved nearly 50 leading physicians and nurses verifying AI’s ability to complete essential checklist items with patients while phase two expanded testing to over 1,000 licensed US nurses and more than 100 US licensed physicians who interacted with AI in simulated patient scenarios.
With phase three testing now underway, Hippocratic AI is engaging its network of over 40 partners, 500 licensed physicians and 5,000 licensed nurses, to conduct thorough safety evaluations of AI products.
Hippocratic AI co-founder and CEO Munjal Shah said: “Our focus on safety testing our product in multiple phases and transparent publication of the results for everyone to see is the next down payment in this safety-first journey.”
In a separate development, Hippocratic AI entered a collaboration with NVIDIA to create empathetic AI healthcare agents using the NVIDIA AI platform.
This partnership aims to achieve super-low-latency conversational interactions, essential for fostering natural emotional connections between patients and AI agents.
